<DOC>
	<DOCNO>NCT00844064</DOCNO>
	<brief_summary>In national Phase I dose-escalation study safety tolerability AP 12009 evaluate adult patient advanced tumor know overproduce TGF-β2 , longer amenable establish therapy .</brief_summary>
	<brief_title>Safety Tolerability AP 12009 , Administered I.V . Patients With Advanced Tumors Known Overproduce TGF-beta-2</brief_title>
	<detailed_description>The purpose dose-finding study evaluate safety tolerability AP 12009 . Two fixed dose-escalation scheme predefined step increase increment select determine maximum tolerate dose ( MTD ) well dose-limiting toxicity ( DLT ) . At least two cycle AP 12009 administer intravenously adult patient acknowledge treatment option . AP 12009 ( trabedersen ) phosphorothioate antisense oligodeoxynucleotide specific mRNA human Transforming Growth Factor beta 2 ( TGF-beta-2 ) . The growth factor TGF-beta play key role malignant progression various tumor induce proliferation , invasion , metastasis , angiogenesis , escape immunosurveillance . In patient pancreatic cancer , colorectal cancer , metastatic melanoma TGF-beta-2 overexpression associate disease stage , clinical prognosis , immunodeficient state patient .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Trabedersen</mesh_term>
	<criteria>1 . Written informed consent . 2 . Age : 1875 year . 3 . Male nonpregnant , nonlactating female . 4. a.Pancreatic cancer : Histologically cytologically confirm diagnosis , stage IVA IVB ( AJCC , 1997 ) . b. Melanoma : Histologically cytologically confirm diagnosis , stage III IV ( AJCC , UICC ) . c. Colorectal cancer : Histologically cytologically confirm diagnosis , stage III IV ( AJCC , UICC ) , exclude last cohort . 5 . Patient longer amenable establish form therapy . 6 . At least one measurable lesion . 7 . Karnofsky performance status least 80 % . 8 . Recovery acute toxicity cause previous therapy . 9 . Adequate organ function assess follow laboratory value : Serum creatinine urea &lt; 2 time upper limit normal ( ULN ) . ALT AST &lt; 3 ULN ( case liver metastasis : &lt; 5x ULN ) ; alkaline phosphatase &lt; 3 ULN ; bilirubin &lt; 2.5 mg/dL . Prothrombin time &lt; 1.5 INR PTT &lt; 1.5 time upper limit normal . Hemoglobin &gt; 9 g/dL . Platelets &gt; 100 x 10E9/L . WBC &gt; 3.0 x 10E9/L . Absolute Neutrophil Count ( ANC ) &gt; 1.5 x 10E9/L . 1 . Patient unable comply protocol regulation . 2 . Pregnant lactate female . 3 . Antitumor radiation therapy within 12 week , tumor surgery within 4 week therapy establish antitumor effect within 2 week prior study entry . 4 . The patient take likely need prohibit concomitant medication . Administration corticosteroids strictly avoid course study . 5 . Patient 's participation another clinical trial investigational medication within 30 day prior study entry . 6 . History brain metastasis . In case suspect brain metastasis CT scan skull perform ( mandatory asymptomatic patient ) . 7 . Clinically significant cardiovascular abnormality refractory hypertension , congestive heart failure , unstable angina , poorly control arrhythmia , myocardial infarction within 6 month prior treatment . 8 . Gastric duodenal ulcer within 6 month study entry risk gastrointestinal ulceration due high consumption NSAIDs . 9 . An active infection HIV , HBV , HCV . 10 . Clinically significant acute viral , bacterial , fungal infection . 11 . Acute medical problem may consider become unacceptable risk , condition might contraindication start study treatment . 12 . History allergy reagent use study . 13 . Drug abuse extensive use alcohol . 14 . Significant psychiatric disorders/ legal incapacity limited legal capacity . 15 . History Long QT Syndrome QTc time ≥ 480 msec screening/baseline ECGs . The average QTc time calculate three separate ECGs perform prior start infusion : two ECGs perform Screening/Baseline ( minimum 1hour interval ) one perform within 1 hour prior start infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Metastatic melanoma</keyword>
	<keyword>Advanced tumor</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Antisense</keyword>
	<keyword>Transforming Growth Factor beta 2</keyword>
	<keyword>Dose escalation</keyword>
</DOC>